Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic Melanoma.
Johnson DB, Bordeaux J, Kim JY, Vaupel C, Rimm DL, Ho TH, Joseph RW, Daud AI, Conry RM, Gaughan EM, Hernandez-Aya LF, Dimou A, Funchain P, Smithy J, Witte JS, McKee SB, Ko J, Wrangle JM, Dabbas B, Tangri S, Lameh J, Hall J, Markowitz J, Balko JM, Dakappagari N. Johnson DB, et al. Among authors: mckee sb. Clin Cancer Res. 2018 Nov 1;24(21):5250-5260. doi: 10.1158/1078-0432.CCR-18-0309. Epub 2018 Jul 18. Clin Cancer Res. 2018. PMID: 30021908 Free PMC article.
Correlates of response and outcomes with talimogene laherperpvec.
Zhou AY, Wang DY, McKee S, Ye F, Wen CC, Wallace DE, Ancell KK, Conry RM, Johnson DB. Zhou AY, et al. J Surg Oncol. 2019 Sep;120(3):558-564. doi: 10.1002/jso.25601. Epub 2019 Jul 2. J Surg Oncol. 2019. PMID: 31264725 Free PMC article.
Talimogene laherparepvec: First in class oncolytic virotherapy.
Conry RM, Westbrook B, McKee S, Norwood TG. Conry RM, et al. Hum Vaccin Immunother. 2018 Apr 3;14(4):839-846. doi: 10.1080/21645515.2017.1412896. Epub 2018 Feb 22. Hum Vaccin Immunother. 2018. PMID: 29420123 Free PMC article. Review.
Clinical characterization of colitis arising from anti-PD-1 based therapy.
Wang DY, Mooradian MJ, Kim D, Shah NJ, Fenton SE, Conry RM, Mehta R, Silk AW, Zhou A, Compton ML, Al-Rohil RN, Lee S, Voorhees AL, Ha L, McKee S, Norrell JT, Mehnert J, Puzanov I, Sosman JA, Chandra S, Gibney GT, Rapisuwon S, Eroglu Z, Sullivan R, Johnson DB. Wang DY, et al. Oncoimmunology. 2018 Oct 31;8(1):e1524695. doi: 10.1080/2162402X.2018.1524695. eCollection 2019. Oncoimmunology. 2018. PMID: 30546965 Free PMC article.
Smoldering myocarditis following immune checkpoint blockade.
Norwood TG, Westbrook BC, Johnson DB, Litovsky SH, Terry NL, McKee SB, Gertler AS, Moslehi JJ, Conry RM. Norwood TG, et al. Among authors: mckee sb. J Immunother Cancer. 2017 Nov 21;5(1):91. doi: 10.1186/s40425-017-0296-4. J Immunother Cancer. 2017. PMID: 29157297 Free PMC article.
Evolution of Immune Checkpoint Blockade-Induced Myocarditis Over 2 Years.
Norwood TG, Lenneman CA, Westbrook BC, Litovsky SH, McKee SB, Conry RM. Norwood TG, et al. Among authors: mckee sb. JACC Case Rep. 2020 Feb 19;2(2):203-209. doi: 10.1016/j.jaccas.2019.11.076. eCollection 2020 Feb. JACC Case Rep. 2020. PMID: 34317205 Free PMC article.
11 results